OBJECTIVE: To examine the potential validity of performance measures and examination-based scales in Friedreich ataxia (FA) by examining their correlation with disease characteristics. METHODS: The authors assessed the properties of a candidate clinical outcome measure, the Friedreich Ataxia Rating Scale (FARS), and simple performance measures (9-hole peg test, the timed 25-foot walk, PATA test, and low-contrast letter acuity) in 155 patients with FA from six institutions, and correlated the scores with disease duration, functional disability, activity of daily living scores, age, and shorter GAA repeat length to assess whether these measures capture the severity of neurologic dysfunction in FA. RESULTS: Scores for the FARS and performance measures correlated significantly with functional disability, activities of daily living scores, and disease duration, showing that these measures meet essential criteria for construct validity for measuring the progressive nature of FA. In addition, the FARS and transformed performance measures scores were predicted by age and shorter GAA repeat length in linear regression models accounting for sex and testing site. Correlations between performance measures were moderate in magnitude, suggesting that each test captures separate yet related dimensions of neurologic function in FA and that a composite measure might better predict disease status. Composite measures created using cohort means and standard deviations predicted disease status better than or equal to single performance measures or examination-based measures. CONCLUSIONS: The Friedreich Ataxia Rating Scale, performance measures, and performance measure composites provide valid assessments of disease progression in Friedreich ataxia.
OBJECTIVE: To examine the potential validity of performance measures and examination-based scales in Friedreich ataxia (FA) by examining their correlation with disease characteristics. METHODS: The authors assessed the properties of a candidate clinical outcome measure, the Friedreich Ataxia Rating Scale (FARS), and simple performance measures (9-hole peg test, the timed 25-foot walk, PATA test, and low-contrast letter acuity) in 155 patients with FA from six institutions, and correlated the scores with disease duration, functional disability, activity of daily living scores, age, and shorter GAA repeat length to assess whether these measures capture the severity of neurologic dysfunction in FA. RESULTS: Scores for the FARS and performance measures correlated significantly with functional disability, activities of daily living scores, and disease duration, showing that these measures meet essential criteria for construct validity for measuring the progressive nature of FA. In addition, the FARS and transformed performance measures scores were predicted by age and shorter GAA repeat length in linear regression models accounting for sex and testing site. Correlations between performance measures were moderate in magnitude, suggesting that each test captures separate yet related dimensions of neurologic function in FA and that a composite measure might better predict disease status. Composite measures created using cohort means and standard deviations predicted disease status better than or equal to single performance measures or examination-based measures. CONCLUSIONS: The Friedreich Ataxia Rating Scale, performance measures, and performance measure composites provide valid assessments of disease progression in Friedreich ataxia.
Authors: Kristin M Rosen; Joanne E Folker; Adam P Vogel; Louise A Corben; Bruce E Murdoch; Martin B Delatycki Journal: J Neurol Date: 2012-06-06 Impact factor: 4.849
Authors: Lauren Myers; Jennifer M Farmer; Robert B Wilson; Lisa Friedman; Amy Tsou; Susan L Perlman; Sub H Subramony; Christopher M Gomez; Tetsuo Ashizawa; George R Wilmot; Katherine D Mathews; Laura J Balcer; David R Lynch Journal: J Neurol Sci Date: 2007-11-07 Impact factor: 3.181
Authors: Karl Egger; Christian Clemm von Hohenberg; Michael F Schocke; Charles R G Guttmann; Demian Wassermann; Marlene C Wigand; Wolfgang Nachbauer; Christian Kremser; Brigitte Sturm; Barbara Scheiber-Mojdehkar; Marek Kubicki; Martha E Shenton; Sylvia Boesch Journal: J Neuroimaging Date: 2013-09-09 Impact factor: 2.486
Authors: Eppie M Yiu; Geneieve Tai; Roger E Peverill; Katherine J Lee; Kevin D Croft; Trevor A Mori; Barbara Scheiber-Mojdehkar; Brigitte Sturm; Monika Praschberger; Adam P Vogel; Gary Rance; Sarah E M Stephenson; Joseph P Sarsero; Creina Stockley; Chung-Yung J Lee; Andrew Churchyard; Marguerite V Evans-Galea; Monique M Ryan; Paul J Lockhart; Louise A Corben; Martin B Delatycki Journal: J Neurol Date: 2015-04-07 Impact factor: 4.849
Authors: David R Lynch; Massimo Pandolfo; Jorg B Schulz; Susan Perlman; Martin B Delatycki; R Mark Payne; Robert Shaddy; Kenneth H Fischbeck; Jennifer Farmer; Paul Kantor; Subha V Raman; Lisa Hunegs; Joanne Odenkirchen; Kristy Miller; Petra Kaufmann Journal: Mov Disord Date: 2012-12-12 Impact factor: 10.338
Authors: Lauren A Seyer; Kristin Galetta; James Wilson; Reiko Sakai; Susan Perlman; Katherine Mathews; George R Wilmot; Christopher M Gomez; Bernard Ravina; Theresa Zesiewicz; Khalaf O Bushara; S H Subramony; Tetsuo Ashizawa; Martin B Delatycki; Alicia Brocht; Laura J Balcer; David R Lynch Journal: J Neurol Date: 2013-06-18 Impact factor: 4.849